依达拉奉联合阿魏酸钠治疗急性脑梗死38例疗效观察

目的探讨依达拉奉联合阿魏酸钠治疗急性脑梗死的临床效果。方法将77例患者随机分为对照组和治疗组,对照给组组予依达拉奉治疗,治疗组给予依达拉奉联合阿魏酸钠治疗。观察2组治疗后血清超氧化物歧化酶(SOD)水平,行美国国立卫生研究院脑卒中量表(NHISS)评分,并对治疗效果进行评价。结果治疗2周后,治疗组SOD水平比治疗前及对照组均显著提高(均P0.05)。治疗4周后,治疗组NHISS评分与治疗前及对照组相比,均显著改善(均P0.05);治疗组有效率高于对照组,但差异无统计学意义(P0.05)。结论依达拉奉联合阿魏酸钠治疗急性脑梗死患者,与单独使用依达拉奉治疗相比,能显著提高体内抗氧化水平,改善患者神经功能评分,提高治疗有效率。     

依达拉奉联合神经节苷脂治疗急性脑梗死对患者神经功能及血液流变学的影响

目的观察依达拉奉联合神经节苷脂治疗急性脑梗死对患者神经功能及血液流变学的影响。方法将2013-02-2015-02我院收治的88例急性脑梗死患者,按照随机数表法分为观察组(44例)和对照组(44例),对照组采用依达拉奉进行常规治疗;观察组在依达拉奉基础上应用神经节苷脂治疗。结果观察组总有效率(93.18%)明显高于对照组(79.55%),差异有统计学意义(P0.05)。观察组不良反应发生率为6.82%,明显低于对照组的15.91%,差异无统计学意义(P0.05)。治疗后第7天,2组神经功能缺损评分明显下降,且观察组神经功能缺损评分为(18.1±3.2)分,明显低于对照组的(21.3±3.9)分,差异有统计学意义(P0.05);但治疗1个疗程后,2组神经功能缺损评分比较差异无统计学意义(P0.05)。治疗后,除红细胞比积外,2组血液流变学各项指标均较治疗前有明显改善,差异具有统计学意义(P0.05)。结论依达拉奉联合神经节苷脂治疗急性脑梗死疗效显著,能够有效促进缺损神经恢复,改善血液流变学。     

依达拉奉联合脑心通治疗老年进展型脑梗死的临床疗效

目的分析依达拉奉联合脑心通治疗老年进展型脑梗死的临床疗效。方法 120例老年进展型脑梗死患者随机分为对照组和观察组各60例。对照组采用依达拉奉治疗,观察组采用依达拉奉联合脑心通治疗。比较2组疗效,治疗前后神经功能缺损程度(NIHSS)、日常生活活动能力(ADL)评分及血液流变学指标。结果治疗14d后观察组NIHSS评分显著低于对照组,ADL量表评分显著高于对照组,观察组总有效率为85.00%,显著高于对照组的65.00%(P0.05)。治疗后第14天观察组全血高切黏度、全血低切黏度、全血中切黏度、血浆黏度、红细胞聚集指数均显著低于对照组,(P0.05)。结论依达拉奉联合脑心通能有效改善PCI神经功能缺失,促进患者日常生活能力的恢复,具有很高的临床应用价值。     

依达拉奉治疗急性大面积脑梗死患者的疗效观察

目的观察依达拉奉治疗急性大面积脑梗死的疗效。方法急性大面积脑梗死患者48例,随机分为依达拉奉治疗组(依达拉奉组,24例)和常规治疗对照组(对照组,24例)。2组患者入院后均给予脑梗死常规治疗,依达拉奉组再给予依达拉奉30mg加入生理盐水100ml静脉滴注,每天2次,连用20～25d。分别于治疗前及治疗后进行神经功能缺损程度评分(NDS)、血浆纤维蛋白原(Fib)、凝血功能、超氧化物歧化酶(SOD)检测,比较两组的疗效。结果2组治疗后NDS比治疗前均有明显降低(均P<0.05),血SOD活力较治疗前明显升高(均P<0.05);依达拉奉组改善程度明显优于对照组(均P<0.05)。2组治疗前后血浆Fib含量、凝血功能差异无统计学意义(均P>0.05)。依达拉奉组的显效率(87.5%)显著高于对照组(45.8%)(P<0.05)。依达拉奉组中出现轻度转氨酶升高2例,尿素氮升高4例,经相应治疗,短期内均恢复正常。结论依达拉奉治疗急性大面积脑梗死的疗效较好,无明显不良反应。     

尤瑞克林联合依达拉奉治疗急性后循环脑梗死疗效观察

目的观察尤瑞克林联合依达拉奉注射液治疗急性后循环脑梗死的疗效。方法将95例急性后循环脑梗死患者随机分为治疗组(尤瑞克林联合依达拉奉)45例和对照组(单用依达拉奉)40例,分别于入院时和治疗后14 d、28 d进行临床神经功能缺损程度(NIHSS)评分,治疗后90 d进行Barthel指数评分;分别在治疗前后测血液流变学并行经颅多普勒(TCD)检查。结果 2组治疗后14 d及28 d神经功能缺损评分均有明显改善,但治疗组与对照组的NIHSS、Barthel指数、血液流变学、TCD变化等比较差异均有统计学意义(P<0.05或P<0.01)。结论尤瑞克林联合依达拉奉可增加急性后循环脑梗死患者的脑血流,改善微循环,并有助于急性后循环脑梗死患者的神经功能恢复。     

大株红景天联合依达拉奉治疗急性脑梗死疗效观察

目的探讨大株红景天注射液联合依达拉奉治疗急性脑梗死的疗效。方法将160例急性脑梗死患者随机分为治疗组和对照组,每组各80例患者,2组均给予抗血小板聚集、降颅内压、控制血压血糖等常规综合治疗以及依达拉奉静滴,治疗组加用大株红景天注射液10mL,观察2组疗效及血清超敏C反应蛋白(hs-CRP)水平的变化。结果治疗2周后,治疗组总有效率高于对照组,且治疗组能进一步降低血清hs-CRP水平。结论大株红景天联合依达拉奉更有利于治疗急性脑梗死,改善患者预后。     

依达拉奉治疗急性脑梗死的效果及对炎症因子与NIHSS评分的影响

目的探讨依达拉奉治疗急性脑梗死的效果及对炎症因子、NIHSS评分的影响。方法选择90例急性脑梗死患者为研究对象,分为2组。对照组给予脑梗死常规治疗,观察组在此基础上加用依达拉奉,比较2组治疗有效率及治疗前后炎症因子水平、NIHSS评分。结果 2组治疗前VEGF、TNF?α比较差异无统计学意义(P0.05),治疗1周、2周后观察组VEGF、TNF?α水平低于对照组,差异有统计学意义(P0.05)。2组治疗前NIHSS评分比较差异无统计学意义,治疗1周、2周后观察组NIHSS评分低于对照组,差异有统计学意义(P0.05)。观察组治疗有效率为91.1%,高于对照组的75.5%,差异有统计学意义(P0.05)。结论依达拉奉治疗急性脑梗死可有效清除自由基、抑制炎症因子水平与氧化反应,减轻神经功能损害,发挥脑保护作用,效果显著,具有重要应用价值。     

依达拉奉联合神经节苷脂治疗急性脑梗死对神经功能及血液流变学的影响

目的探讨依达拉奉联合神经节苷脂治疗急性脑梗死对患者神经功能及血液流变学的影响。方法选择我院收治的126例急性脑梗死患者为研究对象,随机分为对照组和观察组。对照组采用常规治疗+依达拉奉治疗,观察组在对照组的基础上加用神经节苷脂治疗。比较2组治疗前后神经功能改善情况及血液流变学指标改善情况。结果观察组治疗后神经功能缺损评分显著低于对照组,格拉斯哥昏迷评分略高于对照组。治疗后2组血浆黏度、纤维蛋白原、200/S全血黏度切变率、I/S全血黏度切变率显著优于治疗前,观察组改善效果更显著。结论依达拉奉联合神经节苷脂治疗急性脑梗死可显著改善神经功能,改善血液高凝状态,值得临床推广应用。     

巴曲酶联合依达拉奉治疗进展性脑梗死的疗效观察

目的探讨巴曲酶与依达拉奉联合治疗进展性脑梗死的疗效和安全性。方法选取68例进展性脑梗死患者,并随机分成治疗组(巴曲酶+依达拉奉)36例和对照组(依达拉奉)32例,观察2组治疗前后血液流变学指标、血清神经元特异性烯醇化酶(NSE)、美国国立卫生研究院卒中量表(NI HSS)和日常生活活动能力量表(BI)评分的变化,并比较出血率及肝、肾功能损害的发生率。结果治疗组治疗后多项血液流变学指标均有明显降低(P均0.01)。2组治疗后NSE较治疗前均有明显下降(P均0.01)。2组治疗后NI H-SS评分、BI评分比较显示治疗组较对照组的神经功能恢复得更好(P0.05)。2组出血发生率比较差异无显著性(P0.05)。所有病例无严重不良反应发生。结论巴曲酶联合依达拉奉治疗进展性脑梗死安全、有效。     

依达拉奉联合银杏达莫治疗脑梗死的临床疗效

目的探讨依达拉奉联合银杏达莫治疗急性脑梗死的临床效果及对神经功能、炎症因子的影响。方法将100例脑梗死患者按照随机数字表法分为观察组和对照组各50例,对照组在常规治疗的基础上加用银杏达莫,观察组给予依达拉奉联合银杏达莫治疗。比较2组临床效果及神经功能、炎症因子变化情况。结果观察组治疗总有效率为94.00%,高于对照组的80.00%,差异有统计学意义(P0.05);观察组治疗2周、4周时神经功能缺损评分为(13.23±2.38)分、(9.11±1.79)分,均低于对照组,差异有统计学意义(P0.05);治疗4周观察组TNF?α、IL-1、IL-6、血小板聚集率、hs-CRP水平均低于对照组,差异有统计学意义(P0.05)。结论依达拉奉联合银杏达莫显著改善了患者神经功能缺损,降低了炎症因子水平,值得临床重视。     

丹参多酚酸盐联合依达拉奉治疗急性脑梗死对照研究

目的研究丹参多酚酸盐联合依达拉奉治疗急性缺血性脑卒中临床疗效。方法选自郑州大学附属郑州中心医院2015-06—2017-01收治的急性缺血性脑卒中患者92例。按照随机数字表法分为观察者46例与对照组46例。对照组采用依达拉奉治疗,观察组在对照组基础上联合丹参多酚酸盐治疗。2组疗程均为14d。比较2组治疗疗效,以及治疗前后ADL评分、NIHSS评分、血液流变学及炎症因子水平变化。结果观察组总有效率(93.48%)高于对照组(71.47%,P0.05);观察组治疗后ADL评分高于对照组而NIHSS评分低于对照组(t=19.299、19.523,P0.05);观察组治疗后全血高切还原黏度、血浆黏度值、全血低切还原黏度低于对照组(t=11.804、11.161、9.343,P0.05);观察组治疗后CRP和IL-6低于对照组(t=20.421、31.097,P0.05)。结论丹参多酚酸盐联合依达拉奉治疗急性缺血性脑卒中疗效明显,具有重要临床意义。     

依达拉奉联合血栓通对急性脑梗死患者血流变学的影响

目的分析依达拉奉联合血栓通对急性脑梗死患者血流变学的影响,探讨其临床适用性。方法选择2013-05—2014-05于我院就诊的60例急性脑梗死患者,随机分为试验组30例和对照组30例,对照组采用血栓通治疗,试验组在对照组基础上联合依达拉奉进行治疗。观察2组治疗前后NIHSS评分、血脂水平和凝血指标、血液流变学指标的变化情况及治疗后临床疗效。结果治疗前2组NIHSS评分、血脂水平和凝血情况、血流变学相关指标水平比较无明显差异(P0.05),治疗后2组的NIHSS评分、血脂水平和凝血情况、血流变学相关指标水平均明显降低(P0.05),且试验组改善情况优于对照组(P0.05);试验组总有效率为93.33%(28/30),对照组为73.33%(22/30),差异有统计学意义(χ2=4.320 0,P=0.037 7)。2组治疗过程中未出现明显不良反应。结论依达拉奉联合血栓通治疗急性脑梗死安全有效,可有效改善患者的血脂和血流变,降低病情进展危险因素。     

氟桂利嗪与维生素B_(12)对高同型半胱氨酸血症干预治疗的效果

目的考察氟桂利嗪与维生素B_(12)对高同型半胱氨酸血症干预治疗的效果。方法将100例高同型半胱氨酸血症患者随机分为观察组和对照组,每组50例。对照组在给予常规叶酸治疗的基础上加用维生素B12治疗,观察组在此基础上加用氟桂利嗪治疗。比较2组患者治疗前后半胱氨酸水平、血管内皮细胞损伤水平及血流动力学变化。结果 2组患者治疗后半胱氨酸水平与治疗前比较差异具有统计学意义(P0.01),2组间差异无统计学意义(P0.05)。2组患者治疗后血浆内皮素(ET-1)、一氧化氮代谢产物(NO_2~-/NO_3~-)、一氧化氮合酶(NOS)水平与治疗前比较差异具有统计学意义(P0.01),观察组与对照组比较差异具有统计学意义(P0.01)。2组患者治疗后脑动脉最大血流速度(MCAVs)与治疗前比较差异具有统计学意义(P0.01),观察组与对照组比较差异具有统计学意义(P0.01)。结论氟桂利嗪有助于降低血管内皮细胞损伤进而改善患者血流动力学,具有临床应用价值。     

依达拉奉联合尼莫地平对急性大面积脑梗死相关生化指标的影响

目的探讨依达拉奉与尼莫地平对急性大面积脑梗死患者相关生化指标的影响,并评价其安全性。方法选择101例急性大面积脑梗死患者为研究对象,采用计算机数字随机法分为对照组(53例)和观察组(48例)。对照组采用减轻脑水肿、强化他汀以及抗血小板聚集等常规治疗,观察组在对照组基础上给予依达拉奉与尼莫地片联合用药。2组疗程均为15d。观察2组临床疗效、治疗前后血氧饱和度(SpO_2)、血红蛋白(Hb)、总血红蛋白(THb)、还原血红蛋白(HHb)及不良反应发生情况。结果治疗2周后,2组SpO_2、THb、HHb均显著高于同组治疗前,且观察组高于对照组,差异有统计学意义(P0.05);Hb低于同组治疗前,差异有统计学意义(P0.05),2组间比较差异无统计学意义(P0.05)。观察组与对照组总有效率分别为95.83%、73.58%,2组比较差异有统计学意义(χ~2=13.886,P0.05)。治疗期间2组均无明显不良反应。结论在常规治疗基础上,依达拉奉与尼莫地平联合治疗急性大面积脑梗死具有较显著的临床效果,可有效改善患者的神经功能缺损程度,且具有较高的安全性。     

超早期强化降压治疗对基底节区脑出血患者的影响

目的分析超早期强化降压治疗对基底节区脑出血患者血浆基质金属蛋白酶(MMP-9)及神经功能的影响。方法选取2015-07-2016-08信阳市第一人民医院收治的脑出血患者90例为研究对象,随机分为2组各45例。对照组给予常规降压治疗,观察组给予强化降压治疗,对比2组治疗前后NIHSS评分、血浆MMP-9水平、水肿量及血肿量。结果2组治疗前NIHSS评分、血浆MMP-9水平、水肿量及血肿量比较,差异无统计学意义(P0.05),治疗后14d,观察组NIHSS评分明显低于对照组,差异有统计学意义(P0.05);治疗后5d,观察组血浆MMP-9水平及水肿量均明显低于对照组,差异有统计学意义(P0.05);治疗后24h,观察组血肿量明显低于对照组,差异有统计学意义(P0.05)。结论超早期强化降压治疗可有效降低血浆MMP-9水平,减轻神经功能缺损,同时减少血肿量及水肿量,对提高患者预后的生活质量具有重要作用。     

依达拉奉对慢性脑低灌注大鼠脑自由基代谢及海马CA1区HIF-1α表达的影响

目的:观察依达拉奉对慢性脑低灌注大鼠前脑组织SOD、MDA代谢变化及海马CA1区HIF-1α表达的影响,并探讨其意义。方法:实验分假手术组,模型组及依达拉奉组,后两组采用永久性大鼠双侧劲总动脉结扎术(2-vesselocclusion,2VO)制备慢性脑低灌注模型,各组在术后八周后行水迷宫试验后断头,取前脑组织制备成10%脑组织匀浆检测其SOD活性及MDA含量,并采用免疫组化技术观察海马CA1区HIF-1α表达变化。结果:模型组与假手术组相比水迷宫完成时间显著延长(P<0.05),前脑组织SOD活性降低,MDA含量增加(P<0.01),海马CA1区可见HIF-1α少量表达。依达拉奉组较模型组水迷宫结果显著改善(P<0.01),前脑组织SOD活性增加,MDA含量减少(P<0.01),且海马CA1区可见HIF-1α大量表达。结论:慢性脑低灌注可显著损害大鼠空间学习记忆能力,依达拉奉可能通过抑制黄嘌呤氧化酶和次黄嘌呤氧化酶活性,降低羟自由基的浓度,促进HIF-1α表达等多种途径改善血管性认知障。     

依达拉奉联合尤瑞克林治疗急性脑梗死疗效观察

目的探讨依达拉奉联合尤瑞克林治疗急性脑梗死的临床疗效。方法在嵩县人民医院神经内科2014-07—2016?10诊治的急性脑梗死患者中抽取72例为研究对象,随机分为2组,治疗组(n=36)采取依达拉奉联合尤瑞克林治疗,对照组(n=36)应用常规综合治疗,对比2组临床疗效、神经功能变化。结果治疗组总有效率94.4%,高于对照组的77.8%(P0.05);治疗前,2组NIHSS评分对比差异无统计学意义(P0.05);治疗后,治疗组NIHSS评分明显低于对照组(P0.01);治疗组生活质量评分(90.1±1.4)分,高于对照组的(76.3±4.7)分,差异有统计学意义(P0.01)。结论依达拉奉联合尤瑞克林治疗急性脑梗死的临床疗效确切,可有效改善其神经功能。     

丙戊酸钠与无抽搐电休克治疗中老年双相情感障碍躁狂发作的疗效对比

目的对比丙戊酸钠注射液与无抽搐电休克治疗中老年双相情感障碍躁狂发作的疗效。方法选择我院收治的86例中老年双相情感障碍躁狂发作患者,采用随机数表法将86例患者分为对照组43例和观察组43例,2组均予以常规药物治疗,对照组在常规治疗基础上进行无抽搐电休克治疗,观察组予以丙戊酸钠注射液治疗,治疗2周后使用杨式躁狂评定量表(YMRS)评价症状改善情况,使用连线(TMT)测验与威斯康星卡片分类(WCTS)测验比较2组认知功能改善情况,对比2组预后情况。结果治疗后2组YMRS评分与治疗前相比均降低,治疗后1周2组YMRS评分无明显差异(P0.05);治疗后2周观察组YMRS评分显著低于对照组(P0.05);治疗2周后观察组TMT与WCTS结果均优于对照组(P0.05);观察组住院时间、住院费用、复发次数、约束时间和约束次数均低于对照组(P0.05)。结论在中老年双相情感障碍躁狂发作的治疗中应用丙戊酸钠注射液的效果优于无抽搐电休克治疗,可更好改善患者的症状,缩短住院时间,节省治疗费用,值得临床推广。     

Effect of antidepressant treatment on water load test and cortlsol changes in patients with functional dyspepsia

BACKGROUND: It has been demonstrated that patients with functional dyspepsia have experiences social life stress events, and accompanied by psychological disorders, mainly manifested as depression and anxiety. Mental factors can lead to excessive gastrointestinal consensual reaction, and result in different brain-gut axis disturbance, and then cause the gastrointestinal sensorimotor abnormality and endocrine changes. OBJECTIVE: To observe the effect of antidepressant treatment on the changes of water load and serum cortisol in patients with functional dyspepsia, and analyze the therapeutic mechanism. DESIGN: A comparative observation. SETTING: The First Affiliated Hospital o Zhengzhou University. PARTICIPANTS: Forty-five patients with functional dyspepsia accompanied by depression were selected from the Department of Gastroenterology, the First Affiliated Hospital of Zhengzhou University from July 2004 to July 2006, and they were 25–65 years of age, and their disease courses ranged 1–10 years. They were all accorded with the diagnostic standards for RomeⅡfunctional dyspepsia functional dyspepsia. As the patients' will, they were divided into treatment group (n =30, 12 males and 18 females) and control group (n =15, 6 males and 9 females), and there were no significant differences in the data between the two groups (P > 0.05). The programs were discussed and agreed by the committee of medical ethics of the First Affiliated Hospital of Zhengzhou University. Informed contents were obtained from all the patients. METHODS: In the treatment group, the patients were treated with venlafaxine sustained release capsule (75 mg per day), and those with sleep disorder were added by benzodiazepines (alprazolam). In the control group, the patients were given routine treatments of antacid, prokinetics, etc. Before and after 8-week treatment, the following examinations were performed: ① The gastrointestinal symptoms were assessed according to the symptoms; ② The severity of depression was evaluated with Hamilton depression scale (HAMD); ③The relaxation of proximal stomach was observed using water load test; ④ The serum level of cortisol was detected. MAIN OUTCOME MEASURES: ① Symptom score; ② HAMD score; ③ Water load amount; ④ Serum level of cortisol. RESULTS: All the 45 patients were involved in the analysis of results. ① Symptom score: The scores of gastrointestinal symptoms were decreased as compared with those before treatment in both the treatment group and control group (P < 0.05). ② HAMD scores: The scores of HAMD were decreased as compared with those before treatment in both the treatment group and control group (P < 0.05). ③ Water load amount: The total effective rate was significantly higher in the treatment group than the control group (P < 0.05). ④ The serum levels of cortisol after treatment were significantly lower than those before treatment in the patients with severe gastrointestinal symptoms in the treatment group and control group (P < 0.05). CONCLUSION: Antidepressants can normalize the cortisol level of patients with functional dyspepsia, and then decrease gastric sensitivity and ameliorates the receptive relaxation of proximal stomach, also increase the water load amount correspondingly, and finally control the gastrointestinal symptoms of functional dyspepsia.     

急性脑梗死局部亚低温治疗的时间窗研究

目的 探讨局部亚低温治疗急性脑梗死的疗效和最佳治疗时间窗. 方法 将114例急性脑梗死患者按开始接受亚低温治疗时间的不同分为3组,即A组(≤6 h)、B组(6～24 h)和C组(≥24 h),每组再按随机数字表法分为治疗组(A1组、B1组、C1组)和对照组(A2组、B2组、C2组).对照组给予常规抗血小板等治疗,治疗组在常规治疗基础上给予病灶侧局部亚低温治疗48 h.各组患者均在人院时、治疗第7天、治疗第14天、治疗第30天进行美国国立卫生研究院卒中量表(NIHSS)评分,并在入院时及治疗第7天、治疗第14天动态监测血清中一氧化氮(NO)含量、超氧化物歧化酶(SOD)活力. 结果 与A2组、B2组相比,A1组、B1组治疗第7天、治疗第14天、治疗第30天NIHSS评分明显降低,治疗第7天、治疗第14天血清中NO含量明显降低,SOD活力明显升高,差异均有统计学意义(P＜0.05);而C1组在各时间点的NIHSS评分、NO含量、SOD活力与C2组比较差异均无统计学意义(P＞0.05).A1组、B1组在治疗第7天、治疗第14天、治疗第30天NIHSS评分较C1组明显下降,在治疗第7天、治疗第14天NO含量较C1组明显下降,SOD活力较C1组明显提高,差异均有统计学意义(P＜0.05),尤以A1组突出. 结论 早期局部亚低温治疗急性脑梗死临床有效,理想的治疗时间窗为6 h,6～24 h开始亚低温治疗仍有效,但24 h后开始亚低温治疗则无效.

Abstract：

Objective To determine the effect of local mild hypothermia on patients with acute cerebral infarction and ascertain its optimal therapeutic window. Methods According to the time receiving treatment, 114 patients with acute cerebral infarction were divided into group A (≤6 h), group B (6-24 h) and group C (≥ 24 h). Then, each group was subdivided into 2 groups at random: treatment group (A1, B1, C1) and control group (A2, B2, C2). Patients in the control group were subjected to such conventional therapy as anti-platelet aggregation. Patients in the treatment group were treated with local mild hypothermia (33-35 ℃ body-core temperature) for 48 h besides conventional therapy. Clinical outcomes were assessed by the National institutes of health stroke scale (NIHSS) on admission and 7, 14,30 d after treatment. Furthermore, we detected the serum level of nitrogen monoxidum (NO) and superoxide dismutasc (SOD) on admission, and 7 and 14 d after treatment. Results Compared with the control group, treatment group enjoyed significantly decreased scores of NIHSS 7, 14 and 30 d after treatment and significantly decreased level of NO 7 and 14 d after treatment (P＜0.05), but obviously increased SOD vitality 7 and 14 d after treatment (P＜0.05). No significant differences in terms of NIHSS scores, level of NO and SOD vitality were noted between group C1 and group C2 at each time point (P＞0.05). Group Al and group B1 had obviously lower scores of NIHSS than group C1 on the 7th, 14th and 30th d of treatment, and had significantly lower level of NO and obviously increased SOD vitality as compared with group C1 on the 7th and 14th d of treatment (P＜ 0.05), and group A1 enjoyed its advantage.Conclusion Early local mild hypothermia therapy can improve neurological function in patients with acute cerebral infarction. The mild hypothermia induced within 6 h may be optimal therapeutic window;mild hypothermia induced at 6-24 h is less effective and that above 24 h is non-effective.